<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E8EE1BC9-799D-4921-8C12-8689B9552A74"><gtr:id>E8EE1BC9-799D-4921-8C12-8689B9552A74</gtr:id><gtr:firstName>Jon</gtr:firstName><gtr:surname>Frampton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_13057"><gtr:id>5D1701D1-9283-4BA9-A17F-6A9F7A66A7F8</gtr:id><gtr:title>Expanding Interdisciplinary Translational Project Infrastructure.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_13057</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2015-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-05-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>600000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2357078</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS (Professor Ann Logan, CiC: Development of a synthetic anti-scarring membrane dressing for corneal burns)</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8A303C16-23A6-428E-AC04-57F3640B3DA5</gtr:id><gtr:outcomeId>56deed4fbdc7d8.99045661</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>671596</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Experimental Challenge Grant- (Tim Wells and Ian Henderson, CiC: Developing a diagnostic test and novel treatment methods for patients with bronchiectasis and inhibitory antibodies)</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1874FF64-E7B7-4ED8-86B3-C494332ED345</gtr:id><gtr:outcomeId>56dd4b5b4edb63.38059724</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC PhD studentship (Dr Chris Tselepis, CiC: Using alginates for the prevention and treatment of bowel disease)</gtr:description><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>43AF207C-DE11-4CC3-8450-2CFC25E5FDD4</gtr:id><gtr:outcomeId>56deee712e3129.00765580</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>880772</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cell Therapy Catapult (Dr Steven Lee, CiC: Targeting the tumour vasculature with engineered T-cells)</gtr:description><gtr:fundingOrg>Cell Therapy Catapult</gtr:fundingOrg><gtr:id>0D0EB034-D62B-4DBC-8707-381DF8CBC91D</gtr:id><gtr:outcomeId>56deedaf8f6834.08821967</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a biologically acceptable composition for the prophylaxis and/or treatment of colorectal cancer comprising an iron chelator, wherein the composition is adapted for the selective targeting of the iron chelator to the colon.</gtr:description><gtr:grantRef>MC_PC_13057</gtr:grantRef><gtr:id>4888EBE0-1E65-47A9-9F85-86C61A69A7A1</gtr:id><gtr:impact>Priorty no. GB0918722, 26/10/2009</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58ca7704e4f1b4.72184083</gtr:outcomeId><gtr:patentId>WO2011051665, Dr Chris Tselepis</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Anti-cancer Composition Comprising Alginate</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention provides a cell delivery medium comprising a liquid phase, wherein the liquid phase comprises (i) one or more cells suspended within the liquid phase and (ii) a plurality of polymer gel particulates. Methods of producing the cell delivery systems are also provided.</gtr:description><gtr:grantRef>MC_PC_13057</gtr:grantRef><gtr:id>70353526-5E4C-4E68-8AC1-A086B5DC0C5C</gtr:id><gtr:impact>EP2968405, 20/01/2016
US2016045553, 18/02/2016</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58c97b10445e31.64266961</gtr:outcomeId><gtr:patentId>WO2014140549 (Prof. Ann Logan)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Cell Delivery Medium</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to a surgical or wound dressing comprising a sheet of gellan gum and an antifibrotic agent. Methods of producing dressings comprising gellan gums and biologically active agents area also produced.</gtr:description><gtr:grantRef>MC_PC_13057</gtr:grantRef><gtr:id>313D4772-6C99-478F-9026-47ACFBB08A82</gtr:id><gtr:impact>GB201500430, 12/01/2015</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58c97bd2461b02.28836369</gtr:outcomeId><gtr:patentId>WO2016113550	</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Dressing</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Chimeric Therapeutics Ltd</gtr:companyName><gtr:description>The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.

The project is aimed at translating an academic discovery programme funded by Cancer Research UK and developed by Dr Steven Lee and Prof Roy Bicknell at the University of Birmingham into a commercially viable cell therapy.

The collaborating partners have launched a new company, Chimeric Therapeutics Ltd. This new company will hold all future IP rights to the resultant discoveries.</gtr:description><gtr:id>D72D17A4-1240-4344-90CA-86097B3EBECD</gtr:id><gtr:impact>The project is based on a new generation chimeric antigen receptor T-Cell (CAR-T) immuno-oncology therapy for solid tumours. This involves directing the CAR-T cell towards a new, highly specific marker of tumour angiogenesis, CLEC14a. This therapy will act as a vasculature disruptive agent compromising oxygen supply to the tumours and inhibiting tumour growth. The technology is currently undergoing the final stages of preclinical development, and is planned to enter into clinical trials soon after.

The Cell Therapy Catapult will specifically be involved in the project to accelerate the translation of the academic discoveries made in Birmingham with Cancer Research Technology around CAR-T immunotherapies for solid tumours and the CLEC14a target towards a commercially available cell therapy. Immunotherapy is an exciting area in cancer treatment and this technology could provide a powerful route to harness the power of the immune system to block the development of blood vessels, and stop tumours growing.</gtr:impact><gtr:outcomeId>56df03c7e10872.59728567</gtr:outcomeId><gtr:url>http://www.checkcompany.co.uk/company/09842382/CHIMERIC-THERAPEUTICS-LIMITED</gtr:url><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>E3EAF501-D2DB-427B-AF4E-CA4F61AA0DA6</gtr:id><gtr:title>Alginate-Iron Speciation and Its Effect on In Vitro Cellular Iron Metabolism.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4655b0ea30b6d4e921da53394ee1f2b7"><gtr:id>4655b0ea30b6d4e921da53394ee1f2b7</gtr:id><gtr:otherNames>Horniblow RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c8223c49ee73.48998524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>470C38D4-0F08-44BE-818E-C682FE3C0B5E</gtr:id><gtr:title>Cross-species chimeras reveal BamA POTRA and ?-barrel domains must be fine-tuned for efficient OMP insertion.</gtr:title><gtr:parentPublicationTitle>Molecular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18862109bfb4694bd4ce85807b6e389"><gtr:id>f18862109bfb4694bd4ce85807b6e389</gtr:id><gtr:otherNames>Browning DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0950-382X</gtr:issn><gtr:outcomeId>58c8223bea0563.66490242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8A54334-2087-4057-A408-A4B32000E458</gtr:id><gtr:title>Murine Models of Acute Alcoholic Hepatitis and Their Relevance to Human Disease.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28154d7af1e6fe929fe840bbef07537c"><gtr:id>28154d7af1e6fe929fe840bbef07537c</gtr:id><gtr:otherNames>Wilkin RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>58c8223bbb8c50.42551092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>429716B6-C0A7-4E26-9C15-65FD6B0EF2BB</gtr:id><gtr:title>Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13c2577848dab04a02b2b7f8e57a297d"><gtr:id>13c2577848dab04a02b2b7f8e57a297d</gtr:id><gtr:otherNames>Wells TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>58c8223c22ae79.86495027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E37BD04-E122-4C62-B33D-222B87D90C54</gtr:id><gtr:title>Small-Molecule Protein-Protein Interaction Inhibitor of Oncogenic Rho Signaling.</gtr:title><gtr:parentPublicationTitle>Cell chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb28e1cbf74dbea0df0b999f31e4313d"><gtr:id>eb28e1cbf74dbea0df0b999f31e4313d</gtr:id><gtr:otherNames>Diviani D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2451-9448</gtr:issn><gtr:outcomeId>58c8223c742fb8.99771534</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13057</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>